68Ga-DOTA-TATE PET/CT Imaging in NETs

Neuroendocrine Tumors Clinical Trial

Official title:

Pragmatic Study on the Use of 68Ga-DOTA-TATE PET|CT Imaging as a Standard of Care to Influence Clinical Management

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04847505
• Other study ID #: CIMS-2019-02
• Status: Recruiting
• Phase: Phase 3
• Start date: January 1, 2020
• Est. completion date: December 31, 2025

Study information

• Verified date: February 2024
• Source: Centre de recherche du Centre hospitalier universitaire de Sherbrooke
• Contact: Stéphanie Dubreuil
• Phone: 819-346-1110
• Email: Stephanie.Dubreuil2[@]usherbrooke.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is a pragmatic study aiming to evaluate the innocuity/safety profile of the PET radiotracer 68Ga-DOTA-TATE, and to establish the procedure as a routine standard-of-care diagnostic tool for all neuro-endocrine cancer patients. It is a single-center study, but with recruitment across all Canada. The trial is prospective, non-randomized, open-label and with no control group. The superiority of this procedure over the former standard-of-care (Octreoscan) was already established in previous and numerous studies across the world. As such, the current trial aims to gather data to further support the implementation of 68Ga-DOTA-TATE as the new standard-of-care for neuro-endocrine tumors (NET).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Clinical requisition for a 68Ga-DOTA-TATE PET/CT signed by a referring doctor

2. Patients with suspected or proven tumors expressing somatostatin receptors

3. Informed consent by patient (or parents if patient is less than 18 years of age)

Exclusion Criteria:

1. *Pregnancy (not an absolute exclusion). See below*.

2. Patient refusal to participate.

3. Prior severe anaphylactic reaction to DOTA-TATE or somatostatin analogs.

• In the case of a diagnostic procedure in a patient who is or may be pregnant, the principle of benefits-disadvantages would be applied following an in-depth discussion with the treating physicians and the patient. In this context, any clinical situation in which the patient's life would be at stake by excluding her from the study would be considered. The conditions to decide whether to include the patient would be:

• Severe medical condition involving the life of the pregnant woman and/or the fetus;

• Existing treatments that are ineffective or may present toxicity to the woman and/or fetus;

• High clinical suspicion of a somatostatin receptor overexpressing tumour;

• Negative, indeterminate or contraindicated first-line imaging tests;

• Therapeutic gesture considered during pregnancy based on the results of the examination, which may include termination of pregnancy or premature delivery;

• Documented discussion with the treating team and the patient;

• Patient agrees.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Diagnostic Test:
• 68Ga-DOTA-TATE
The intervention consists of an intravenous injection of the radiopharmaceutical 68Ga-DOTA-TATE and a physiological saline flush, followed 45-90 minutes later by a PET/CT image acquisition.

Locations

Country	Name	City	State
Canada	CHUS	Sherbrooke	Quebec

Sponsors (2)

Lead Sponsor	Collaborator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke	Université de Sherbrooke

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile of 68Ga-DOTA-TATE	Following the injection, the patient will be explicitly reminded of possible symptoms and undesirable events. The patient will be advised to inform the study personnel of the occurrence of any events, at the most opportune time. The patient will be instructed to call the local nuclear medicine study coordinator for any undesirable event that may occur for 48 hours after the PET/CT scan.; Safety will be assessed by compiling all reported adverse events. Adverse events reported by patients or observed by the investigator will be recorded in the patients' CRFs, the AE database, and reported to the research manager.	5 years
Secondary	Generate clinical information on the impact of 68Ga-DOTA-TATE for NET patient management	Neuroendocrine tumors (NET) used to be difficult to diagnose early with conventional methods, but with the advent of new-generation Somatostatin Receptor radioligands such as 68Ga-DOTA-TATE precise and early detection is now frequent. This trial offers the opportunity to evaluate the impact of this state-of-the-art diagnostic procedure on the management of NET patients on a large, nation-wide cohort. As such, the research team will monitor the clinical gain of 68Ga-DOTA-TATE on the diagnostic and management of NETs regarding sensitivity, specificity and accuracy compared to previous diagnostic methods.	5 years
Secondary	Instigate the routine standard-of-care use of 68Ga-DOTA-TATE for NET patients	Clinical and scientific evidences showed that 68Ga-DOTA-TATE is vastly superior as a diagnostic tool than the current standard-of-care Octreoscan. As such, this trial aims to implement 68Ga-DOTA-TATE as the new standard-of-care for precision diagnostic of NETs. In order to do so, health policy agencies (most notably Health Canada) will be notified about the gains (or the flaws if any) of 68Ga-DOTA-TATE over the current standard-of-care (Octreoscan) for the precise diagnostic and follow-up of NETs that will be observed during the present study. The safety profile and diagnostic accuracy assessed in Outcome 1 and 2 will be used to convince the authorities of the net benefit of using this procedure rather than the "old" standard-of-care.	5 years